Burning Rock Biotech received a Hold rating and price target from Jefferies analyst today.Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence
Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The word on The Street in general, suggests a Hold analyst consensus rating for Burning Rock Biotech.
Based on Burning Rock Biotech’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $126.32 million and a GAAP net loss of $15.39 million. In comparison, last year the company earned a revenue of $126.02 million and had a GAAP net loss of $81.29 million
